Bloomberg -- Roche Holding AG, Johnson & Johnson and Biogen Idec Inc. are being urged by U.S. regulators to evaluate their hepatitis, cancer and anemia drugs for less- common ailments, after an incentive program to generate research into new medicines for neglected diseases failed.
